Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women.

Spurdle AB, Hopper JL, Chen X, McCredie MR, Giles GG, Venter DJ, Southey MC, Chenevix-Trench G.

Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):439-43.

2.

The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.

Spurdle AB, Hopper JL, Chen X, Dite GS, McCredie MR, Giles GG, Venter DJ, Southey MC, Purdie DM, Chenevix-Trench G.

Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1287-93.

3.

Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50.

Wang-Gohrke S, Chang-Claude J, Becher H, Kieback DG, Runnebaum IB.

Cancer Res. 2000 May 1;60(9):2348-50.

4.

Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women.

Suter NM, Malone KE, Daling JR, Doody DR, Ostrander EA.

Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):127-35.

5.

Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies.

Johnatty SE, Spurdle AB, Beesley J, Chen X, Hopper JL, Duffy DL, Chenevix-Trench G; Kathleen Cuningham Consortium for Research in Familial Breast Cancer.

Breast Cancer Res Treat. 2008 May;109(1):91-9. Epub 2007 Jun 26.

PMID:
17592773
6.

No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer.

Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G.

Carcinogenesis. 2001 May;22(5):717-21.

PMID:
11323389
7.

The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years.

Spurdle AB, Hopper JL, Chen X, Dite GS, Cui J, McCredie MR, Giles GG, Ellis-Steinborner S, Venter DJ, Newman B, Southey MC, Chenevix-Trench G.

Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):413-6.

8.

Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer.

Webb PM, Hopper JL, Newman B, Chen X, Kelemen L, Giles GG, Southey MC, Chenevix-Trench G, Spurdle AB.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):319-23.

9.

P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer.

Naidu R, Har YC, Taib NA.

J Exp Clin Cancer Res. 2007 Mar;26(1):133-40.

PMID:
17550142
10.

A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk.

De Vivo I, Hankinson SE, Colditz GA, Hunter DJ.

Cancer Res. 2003 Sep 1;63(17):5236-8.

11.

Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer risk.

Sillanpää P, Hirvonen A, Kataja V, Eskelinen M, Kosma VM, Uusitupa M, Vainio H, Mitrunen K.

Pharmacogenetics. 2004 Apr;14(4):239-45.

PMID:
15083068
12.

CASP8 polymorphisms, estrogen and progesterone receptor status, and breast cancer risk.

Han S, Lee KM, Choi JY, Park SK, Lee JY, Lee JE, Noh DY, Ahn SH, Han W, Kim DH, Hong YC, Ha E, Yoo KY, Kang D.

Breast Cancer Res Treat. 2008 Jul;110(2):387-93. Epub 2007 Oct 17.

PMID:
17940865
13.

Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.

Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, Zheng W.

J Natl Cancer Inst. 2000 Mar 1;92(5):412-7.

PMID:
10699071
14.

Association of breast cancer risk with a GT dinucleotide repeat polymorphism upstream of the estrogen receptor-alpha gene.

Cai Q, Gao YT, Wen W, Shu XO, Jin F, Smith JR, Zheng W.

Cancer Res. 2003 Sep 15;63(18):5727-30.

15.

A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.

Singh V, Rastogi N, Sinha A, Kumar A, Mathur N, Singh MP.

Breast Cancer Res Treat. 2007 Jan;101(1):73-81. Epub 2006 Jun 29. Erratum in: Breast Cancer Res Treat. 2007 Apr;102(2):249.

PMID:
16807674
16.

A population-based case-control study of the Arg399Gln polymorphism in DNA repair gene XRCC1 and risk of breast cancer.

Shu XO, Cai Q, Gao YT, Wen W, Jin F, Zheng W.

Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1462-7.

17.

Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women.

Ren Z, Cai Q, Shu XO, Cai H, Li C, Yu H, Gao YT, Zheng W.

Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1290-5.

18.

Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years.

Spurdle AB, Dite GS, Chen X, Mayne CJ, Southey MC, Batten LE, Chy H, Trute L, McCredie MR, Giles GG, Armes J, Venter DJ, Hopper JL, Chenevix-Trench G.

J Natl Cancer Inst. 1999 Jun 2;91(11):961-6.

PMID:
10359549
19.

Folate intake, methylenetetrahydrofolate reductase polymorphisms, and breast cancer risk in women from the Malmö Diet and Cancer cohort.

Ericson U, Sonestedt E, Ivarsson MI, Gullberg B, Carlson J, Olsson H, Wirfält E.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1101-10. doi: 10.1158/1055-9965.EPI-08-0401. Epub 2009 Mar 31.

20.

Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk.

Quick SK, Shields PG, Nie J, Platek ME, McCann SE, Hutson AD, Trevisan M, Vito D, Modali R, Lehman TA, Seddon M, Edge SB, Marian C, Muti P, Freudenheim JL.

Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1082-7. doi: 10.1158/1055-9965.EPI-07-2755.

Supplemental Content

Support Center